E
MediPharm Labs Corp.
MEDIF
$0.0518
$0.00081.57%
E
Sell
3/10/2025Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 3/10/2025 due to a decline in the volatility index and growth index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 3/10/2025 due to a decline in the volatility index and growth index.
D
Sell
2/19/2025Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 2/19/2025 due to an increase in the volatility index, growth index and total return index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 2/19/2025 due to an increase in the volatility index, growth index and total return index.
E
Sell
1/29/2025Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 1/29/2025 due to a decline in the volatility index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 1/29/2025 due to a decline in the volatility index.
D
Sell
1/13/2025Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 1/13/2025 due to an increase in the total return index and volatility index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 1/13/2025 due to an increase in the total return index and volatility index.
E
Sell
12/20/2024Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 12/20/2024 due to a decline in the growth index, volatility index and valuation index. EBIT declined 13.14% from -$1.77M to -$2M, total revenue declined 5.03% from $7.56M to $7.18M, and earnings per share declined from -$0.0047 to -$0.0049.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 12/20/2024 due to a decline in the growth index, volatility index and valuation index. EBIT declined 13.14% from -$1.77M to -$2M, total revenue declined 5.03% from $7.56M to $7.18M, and earnings per share declined from -$0.0047 to -$0.0049.
D
Sell
10/14/2024Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 10/14/2024 due to an increase in the volatility index and total return index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 10/14/2024 due to an increase in the volatility index and total return index.
E
Sell
9/24/2024Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 9/24/2024 due to a decline in the volatility index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 9/24/2024 due to a decline in the volatility index.
D
Sell
9/9/2024Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 9/9/2024 due to a substantial increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0066 to -$0.0047, EBIT increased 7.55% from -$1.91M to -$1.77M, and total revenue increased 4.37% from $7.25M to $7.56M.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 9/9/2024 due to a substantial increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0066 to -$0.0047, EBIT increased 7.55% from -$1.91M to -$1.77M, and total revenue increased 4.37% from $7.25M to $7.56M.
E
Sell
8/15/2024Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 8/15/2024 due to a decline in the total return index and volatility index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 8/15/2024 due to a decline in the total return index and volatility index.
D
Sell
7/26/2024Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 7/26/2024 due to an increase in the volatility index and total return index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 7/26/2024 due to an increase in the volatility index and total return index.
E
Sell
7/9/2024Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 7/9/2024 due to a decline in the volatility index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 7/9/2024 due to a decline in the volatility index.
D
Sell
6/20/2024Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 6/20/2024 due to an increase in the volatility index and valuation index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 6/20/2024 due to an increase in the volatility index and valuation index.
E
Sell
6/4/2024Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 6/4/2024 due to a substantial decline in the growth index, volatility index and solvency index. Operating cash flow declined 204.48% from $1.08M to -$1.13M, EBIT declined 175.48% from $2.53M to -$1.91M, and earnings per share declined from -$0.0049 to -$0.0066.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 6/4/2024 due to a substantial decline in the growth index, volatility index and solvency index. Operating cash flow declined 204.48% from $1.08M to -$1.13M, EBIT declined 175.48% from $2.53M to -$1.91M, and earnings per share declined from -$0.0049 to -$0.0066.
D
Sell
6/3/2024Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index and total return index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 6/3/2024 due to an increase in the volatility index and total return index.
E
Sell
5/16/2024Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 5/16/2024 due to a decline in the volatility index and growth index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 5/16/2024 due to a decline in the volatility index and growth index.
D
Sell
4/17/2024Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 4/17/2024 due to an increase in the solvency index, volatility index and total return index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 4/17/2024 due to an increase in the solvency index, volatility index and total return index.
E
Sell
4/1/2024Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 4/1/2024 due to a decline in the solvency index, volatility index and valuation index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 4/1/2024 due to a decline in the solvency index, volatility index and valuation index.
D
Sell
3/11/2024Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 3/11/2024 due to an increase in the total return index and volatility index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 3/11/2024 due to an increase in the total return index and volatility index.
E
Sell
2/23/2024Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 2/23/2024 due to a decline in the total return index, volatility index and growth index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 2/23/2024 due to a decline in the total return index, volatility index and growth index.
D
Sell
1/11/2024Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 1/11/2024 due to an increase in the volatility index and total return index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 1/11/2024 due to an increase in the volatility index and total return index.
E
Sell
12/26/2023Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 12/26/2023 due to a decline in the volatility index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 12/26/2023 due to a decline in the volatility index.
D
Sell
12/5/2023Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 12/5/2023 due to an increase in the volatility index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 12/5/2023 due to an increase in the volatility index.
E
Sell
11/17/2023Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 11/17/2023 due to a decline in the volatility index and valuation index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 11/17/2023 due to a decline in the volatility index and valuation index.
D
Sell
10/18/2023Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 10/18/2023 due to a noticeable increase in the total return index, volatility index and solvency index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 10/18/2023 due to a noticeable increase in the total return index, volatility index and solvency index.
E
Sell
3/14/2023Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D on 03/14/2023.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
MediPharm Labs Corp. (MEDIF) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D on 02/08/2023.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D on 02/08/2023.
D
Sell
1/31/2023Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D from D- on 1/31/2023 due to an increase in the growth index, total return index and volatility index. Total revenue increased 62.88% from $3.42M to $5.57M, operating cash flow increased 61.89% from -$5.81M to -$2.21M, and EBIT increased 10.31% from -$5.33M to -$4.78M.
MediPharm Labs Corp. (MEDIF) was upgraded to D from D- on 1/31/2023 due to an increase in the growth index, total return index and volatility index. Total revenue increased 62.88% from $3.42M to $5.57M, operating cash flow increased 61.89% from -$5.81M to -$2.21M, and EBIT increased 10.31% from -$5.33M to -$4.78M.
D
Sell
5/20/2022Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 5/20/2022 due to a substantial increase in the growth index. Earnings per share increased from -$0.0592 to -$0.0237, and EBIT increased 55.13% from -$13.76M to -$6.17M.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 5/20/2022 due to a substantial increase in the growth index. Earnings per share increased from -$0.0592 to -$0.0237, and EBIT increased 55.13% from -$13.76M to -$6.17M.
E
Sell
4/18/2022Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 4/18/2022 due to a major decline in the growth index, solvency index and volatility index. Operating cash flow declined 1,564.28% from -$192.9 to -$3.21M, earnings per share declined from -$0.0238 to -$0.0592, and EBIT declined 122.56% from -$6.18M to -$13.76M.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 4/18/2022 due to a major decline in the growth index, solvency index and volatility index. Operating cash flow declined 1,564.28% from -$192.9 to -$3.21M, earnings per share declined from -$0.0238 to -$0.0592, and EBIT declined 122.56% from -$6.18M to -$13.76M.
D
Sell
11/16/2021Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 11/16/2021 due to a noticeable increase in the growth index. Operating cash flow increased 91.97% from -$2.4M to -$192.9, earnings per share increased from -$0.0407 to -$0.0238, and EBIT increased 32.15% from -$8.72M to -$5.92M.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 11/16/2021 due to a noticeable increase in the growth index. Operating cash flow increased 91.97% from -$2.4M to -$192.9, earnings per share increased from -$0.0407 to -$0.0238, and EBIT increased 32.15% from -$8.72M to -$5.92M.
E
Sell
11/8/2021Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
5/18/2021Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 5/18/2021 due to an increase in the solvency index, growth index and volatility index. Debt to equity declined from 0.23 to 0.03, the quick ratio increased from 2.31 to 4.15, and EBIT increased 69.96% from -$20.81M to -$6.25M.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 5/18/2021 due to an increase in the solvency index, growth index and volatility index. Debt to equity declined from 0.23 to 0.03, the quick ratio increased from 2.31 to 4.15, and EBIT increased 69.96% from -$20.81M to -$6.25M.
E
Sell
5/10/2021Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 5/10/2021 due to a decline in the volatility index.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 5/10/2021 due to a decline in the volatility index.
D
Sell
4/20/2021Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 4/20/2021 due to an increase in the volatility index and total return index.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E+ on 4/20/2021 due to an increase in the volatility index and total return index.
E
Sell
4/5/2021Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 4/5/2021 due to a decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.0826 to -$0.1637, EBIT declined 64.44% from -$12.57M to -$20.67M, and the quick ratio declined from 4.52 to 2.31.
MediPharm Labs Corp. (MEDIF) was downgraded to E+ from D- on 4/5/2021 due to a decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.0826 to -$0.1637, EBIT declined 64.44% from -$12.57M to -$20.67M, and the quick ratio declined from 4.52 to 2.31.
D
Sell
9/11/2020Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to D- from D on 9/11/2020 due to a large decline in the solvency index, volatility index and total return index.
MediPharm Labs Corp. (MEDIF) was downgraded to D- from D on 9/11/2020 due to a large decline in the solvency index, volatility index and total return index.
D
Sell
8/14/2020Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D from D- on 8/14/2020 due to an increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.0968 to -$0.0144, EBIT increased 80.07% from -$16.32M to -$3.25M, and operating cash flow increased 64.23% from -$11.46M to -$4.1M.
MediPharm Labs Corp. (MEDIF) was upgraded to D from D- on 8/14/2020 due to an increase in the growth index, solvency index and valuation index. Earnings per share increased from -$0.0968 to -$0.0144, EBIT increased 80.07% from -$16.32M to -$3.25M, and operating cash flow increased 64.23% from -$11.46M to -$4.1M.
D
Sell
6/19/2020Downgrade
MediPharm Labs Corp. (MEDIF) was downgraded to D- from D on 6/19/2020 due to a large decline in the efficiency index, total return index and growth index. Operating cash flow declined 1,536.05% from $797.8 to -$11.46M, EBIT declined 931% from -$1.58M to -$16.32M, and net income declined 421.32% from -$2.44M to -$12.72M.
MediPharm Labs Corp. (MEDIF) was downgraded to D- from D on 6/19/2020 due to a large decline in the efficiency index, total return index and growth index. Operating cash flow declined 1,536.05% from $797.8 to -$11.46M, EBIT declined 931% from -$1.58M to -$16.32M, and net income declined 421.32% from -$2.44M to -$12.72M.
D
Sell
11/5/2019Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D from D- on 11/5/2019 due to an increase in the solvency index, efficiency index and volatility index. Net income increased 489.55% from -$383.6 to $1.49M, total capital increased 221.45% from $30.23M to $97.18M, and the quick ratio increased from 0.63 to 1.87.
MediPharm Labs Corp. (MEDIF) was upgraded to D from D- on 11/5/2019 due to an increase in the solvency index, efficiency index and volatility index. Net income increased 489.55% from -$383.6 to $1.49M, total capital increased 221.45% from $30.23M to $97.18M, and the quick ratio increased from 0.63 to 1.87.
D
Sell
7/1/2019Upgraded
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E on 7/1/2019 due to a large increase in the solvency index, growth index and total return index. Operating cash flow increased 439.36% from -$896.1 to $3.04M, total revenue increased 113.67% from $7.73M to $16.51M, and earnings per share increased from -$0.0097 to -$0.0037.
MediPharm Labs Corp. (MEDIF) was upgraded to D- from E on 7/1/2019 due to a large increase in the solvency index, growth index and total return index. Operating cash flow increased 439.36% from -$896.1 to $3.04M, total revenue increased 113.67% from $7.73M to $16.51M, and earnings per share increased from -$0.0097 to -$0.0037.
E
Sell
4/9/2019Downgrade
MediPharm Labs Corp. (MLCPF) was downgraded to E from E+ on 4/9/2019 due to a decline in the valuation index.
MediPharm Labs Corp. (MLCPF) was downgraded to E from E+ on 4/9/2019 due to a decline in the valuation index.
E
Sell
4/1/2019Upgraded
MediPharm Labs Corp. (MLCPF) was upgraded to E+ from E on 4/1/2019 due to a noticeable increase in the total return index.
MediPharm Labs Corp. (MLCPF) was upgraded to E+ from E on 4/1/2019 due to a noticeable increase in the total return index.
E
Sell
2/15/2019Upgraded
MediPharm Labs Corp. (MLCPF) was upgraded to E from E- on 2/15/2019 due to an increase in the volatility index and total return index.
MediPharm Labs Corp. (MLCPF) was upgraded to E from E- on 2/15/2019 due to an increase in the volatility index and total return index.
E
Sell
1/28/2019Downgrade
MediPharm Labs Corp. (MLCPF) was downgraded to E- from E on 1/28/2019 due to a decline in the volatility index and valuation index.
MediPharm Labs Corp. (MLCPF) was downgraded to E- from E on 1/28/2019 due to a decline in the volatility index and valuation index.
E
Sell
1/11/2019Upgraded
MediPharm Labs Corp. (MLCPF) was upgraded to E from E- on 1/11/2019 due to a noticeable increase in the volatility index and total return index.
MediPharm Labs Corp. (MLCPF) was upgraded to E from E- on 1/11/2019 due to a noticeable increase in the volatility index and total return index.
E
Sell
1/3/2019None
MediPharm Labs Corp. (MEDIF) was downgraded to E- from U on 01/03/2019.
MediPharm Labs Corp. (MEDIF) was downgraded to E- from U on 01/03/2019.
OTC PK
03/11/2025 12:42PM Eastern
Quotes delayed
